Gene therapy offers great hope for patients, but comes with a bevy of challenges for patients and payers alike.
Here’s five things to take away from Anthem’s launch of PBM IngenioRx.
Jim Barlow of Geneos Therapeutics explains the role of value networks and strategies to increase cell therapy access.
Experts discuss what these trends entail, what’s giving them momentum, and how executives can get on board.
Evidence grows that these nonclinical factors have a large influence on patient outcomes. Here’s what hospitals and payers can do about it.
The value and benefits of biosimilars are increasingly becoming more apparent. Here are four areas where they are growing the most.
This comprehensive, pay-for-performance approach drives clinical quality and affordability.
Biosimilar agents can help healthcare organizations offer patients more options for their care. So, what’s stopping payers from immediately adding them to their formularies?
Two transformational multibillion-dollar deals in the healthcare and pharmacy industries have been in the works for months—the $69 billion CVS-Aetna merger and the $52 billion Cigna-Express Scripts merger—despite concerns that more consol
Payers challenged a 2014 CMS Overpayment Rule and won. Here’s what healthcare executives should know.